ライフサイエンスコーパス: ecto-5'-nucleotidase

1 ted into adenosine by the extracellular CD73/ecto-5-nucleotidase.

2 PAP suppresses pain by functioning as an ecto-5'-nucleotidase.

3 ition is mediated by selective inhibition of ecto-5'-nucleotidase.

4 rch for potential targets of zinc other than ecto-5'-nucleotidase.

5 serial actions of ecto-phosphodiesterase and ecto-5'-nucleotidase.

6 e feedforward ADP-mediated inhibition of the ecto-5'-nucleotidase.

7 The adenosine producing enzyme ecto-5'-nucleotidase (5'-NT) is not normally expressed d

8 NTPD; cluster of differentiation (CD)39] and ecto-5'-nucleotidase (5'-NT; CD73), among others.

9 These results not only show that ecto-5'-nucleotidase activity is a critical mediator of

10 The NudP ecto-5'-nucleotidase activity is reminiscent of the reac

11 Because the ecto-5'-nucleotidase activity of CD73 catalyzes AMP brea

12 recombinant NudP revealed a Mn(2+)-dependent ecto-5'-nucleotidase activity on ribo- and deoxyribonucl

13 ,beta-methylene-ADP, often used to block the ecto-5'-nucleotidase, also inhibited voltage-gated K(+)

14 ice lacking A2A adenosine receptor (A2AR) or ecto-5'nucleotidase (an enzyme that converts extracellul

15 This study tested the hypothesis that CD73 (ecto-5'nucleotidase), an enzyme that catalyzes the conve

16 ow that NKT cells express both CD39 and CD73/ecto-5'-nucleotidase and can therefore generate adenosin

17 bolism, adenosine is generated by the enzyme ecto-5'-nucleotidase, and adenosine production and adeno

18 of fibroblast-like cells (e.g., collagen I, ecto-5'-nucleotidase, and PDGF receptor-beta).

19 but not with this solution plus a blocker of ecto-5'-nucleotidase (AOPCP).

20 eletal muscle fibres and dephosphorylated by ecto 5'nucleotidase bound to the sarcolemma.

21 he expression of mRNAs for ENPP1, NTPD1, and ecto-5'-nucleotidase, but not NTPD2 (ecto-ATPase, or CD3

22 ation in the supernate of cells deficient in ecto-5'-nucleotidase, but there is a marked increase in

23 extracellular adenosine as generated by the ecto-5'-nucleotidase CD73 in fibrosis development after

24 generates AMP, which is in turn used by the ecto-5'-nucleotidase CD73 to synthesize adenosine.

25 An inhibitor of the ecto-5'-nucleotidase CD73, alpha, beta-methylene ADP (AO

26 The ecto-5'-nucleotidase CD73, an ectoenzyme highly expresse

27 adenosine, produced through the activity of ecto-5'-nucleotidase CD73, elicits potent immunosuppress

28 eNAD+ exposure reduced the expression of the ecto-5'-nucleotidase CD73, the nicotinamide adenine mono

29 nd the immunosuppressive cell surface enzyme ecto-5'-nucleotidase CD73.

30 In this pathway, ecto-5-nucleotidase CD73 has the unique function of regu

31 ] to adenosine monophosphate [AMP]) and CD73 ecto-5'-nucleotidase (CD73 converts AMP to adenosine).

32 the accumulation of adenosine and increased ecto-5'-nucleotidase (CD73) and adenosine A(2B) receptor

33 known as "Treg") express apyrases (CD39) and ecto-5'-nucleotidase (CD73) and contribute to their inhi

34 on selective channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1.

35 etabolized to adenosine by surface-expressed ecto-5'-nucleotidase (CD73) and subsequently activates s

36 mponent of the purinergic system, the enzyme ecto-5'-nucleotidase (CD73) catalyzes the last step in t

37 Ecto-5'-nucleotidase (CD73) catalyzes the terminal phosp

38 Because ecto-5'-nucleotidase (CD73) catalyzes the terminal step

39 Production of anti-inflammatory adenosine by ecto-5'-nucleotidase (CD73) helps maintain endothelial b

40 nce staining, we confirmed the expression of ecto-5'-nucleotidase (CD73) in trigeminal nociceptive ne

41 We show that inhibition of ecto-5'-nucleotidase (CD73) in vitro reduces carotid bod

42 Ecto-5'-nucleotidase (CD73) is a central surface enzyme

43 Subsequently, we determined that ecto-5'-nucleotidase (CD73) is a key enzyme required for

44 Ecto-5'-nucleotidase (CD73) is central to the generation

45 Ecto-5'-nucleotidase (CD73) is expressed abundantly on t

46 The current work evaluated whether ecto-5'-nucleotidase (CD73) is important in promoting ca

47 Ecto-5'-nucleotidase (CD73) is the main enzyme responsib

48 Nucleotide phosphohydrolysis by the ecto-5'-nucleotidase (CD73) is the main source for extra

49 mechanism, K8/K18 accumulation and increased ecto-5'-nucleotidase (CD73) levels were noted.

50 Ecto-5'-nucleotidase (CD73) on immune cells is emerging

51 lammatory response, we evaluated the role of ecto-5'-nucleotidase (CD73) on the development of heart

52 1; CD39) to AMP, which then is hydrolyzed by ecto-5'-nucleotidase (CD73) to adenosine.

53 In addition, increased activity of ecto-5'-nucleotidase (CD73) was found in the lungs in co

54 In contrast, a subset expressing Ecto-5'-nucleotidase (CD73) was retained and a specific

55 hosphate (ATP) diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73) were increased twofold to th

56 in CA1 than in the DG, and concentrations of ecto-5'-nucleotidase (CD73) were much higher in CA1.

57 Levels of ecto-5'-nucleotidase (CD73), an enzyme that converts ext

58 The present study investigated whether ecto-5'-nucleotidase (CD73), an enzyme that generates ad

59 Ecto-5'-nucleotidase (CD73), encoded by NT5E, is the maj

60 role of the adenosine-generating ectoenzyme, ecto-5'-nucleotidase (CD73), in regulating immune and or

61 We investigated whether ecto-5'-nucleotidase (CD73), the "pacemaker" enzyme of e

62 Ecto-5'-nucleotidase (CD73), the enzyme that generates a

63 We now show that ecto-5'-nucleotidase (CD73), the major enzyme able to co

64 osine-monophosphate (AMP) through the enzyme ecto-5'-nucleotidase (CD73), we examined the contributio

65 activity of the adenosine-generating enzyme, ecto-5'-nucleotidase (CD73), which was significantly low

66 e triphosphate diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73).

67 by the terminal enzymatic step catalyzed by ecto-5'-nucleotidase (CD73).

68 feedback) in mice with targeted deletion of ecto-5'-nucleotidase/CD73 (e-5'NT/CD73), the enzyme resp

69 riphosphate diphosphohydrolase (NTPDase) and ecto-5'-nucleotidase/CD73 activities in thoracic aortas,

70 ate diphosphohydrolase-1 (NTPDase1/CD39) and ecto-5'-nucleotidase/CD73 activities were measured in 22

71 Wild type, ecto-5'-nucleotidase-deficient, and adenosine receptor-d

72 oustic stimuli are paired with disruption of ecto-5'-nucleotidase-dependent adenosine production or A

73 pression of CD39/ENTPD1 in concert with CD73/ecto-5'-nucleotidase distinguishes CD4(+)/CD25(+)/Foxp3(

74 more potent against c-N-I than the membrane ecto-5'-nucleotidase (e-N).

75 mediated the conversion of AMP to adenosine: ecto 5'-nucleotidase (ecto 5'-NT, CD73) and alkaline pho

76 ytosolic 5'-nucleotidase and an elevation of ecto-5'-nucleotidase (ecto-5'-NT).

77 We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-boun

78 ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis

79 1(high) cells correlated with high levels of ecto-5'-nucleotidase enzymatic activity.

80 t publications have reported attenuated CD73/ecto-5'-nucleotidase expression in patients with EoE, wh

81 high) subset had the highest levels of CD73 (ecto-5'-nucleotidase) expression (Deltamean fluorescence

82 ytosol, while release of AMP and affinity of ecto 5'nucleotidase for AMP are increased by acidosis.

83 te (AMP-CP), and a competitive substrate for ecto-5'-nucleotidase (guanosine monophosphate, GMP) did

84 test the role of adenosine generated by CD73/ecto-5'-nucleotidase in GVHD.

85 Zinc was a less potent inhibitor of ecto-5'-nucleotidase in vitro than the nucleotide analog

86 have directly studied the properties of the ecto-5'-nucleotidase in Xenopus embryo spinal cord.

87 Because ecto 5' nucleotidase inhibitor (alpha,beta-methylene ade

88 etreated cells to activated neutrophils; the ecto-5'-nucleotidase inhibitor alpha, beta-methylene ade

89 orescent beads was inhibited by ATP, but the ecto-5'-nucleotidase inhibitor alpha, beta-methylene ADP

90 Addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP

91 ignal was greatly reduced by addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP

92 The ecto-5'-nucleotidase inhibitor alphabeta-meADP significa

93 by 40.4 +/- 2.8%, while AOPCP (12.5 mm), an ecto-5'-nucleotidase inhibitor that increases extracellu

94 of inflammation, and injection of APCP, the ecto-5'-nucleotidase inhibitor, abrogates completely the

95 to adenosine using a combination of a potent ecto-5'-nucleotidase inhibitor, alpha,beta-methylene ade

96 leoside transporter inhibitor; APCP, a CD73 (ecto-5'-nucleotidase) inhibitor; or cold adenosine signi

97 3 in EPEC infection by testing the effect of ecto-5'-nucleotidase inhibitors.

98 CD73/ecto-5'-nucleotidase is an enzyme that generates adenosi

99 We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and establish

100 During exercise, the concentration of ecto 5'nucleotidase may be increased by translocation fr

101 of evidence that adenosine results from the ecto-5'-nucleotidase- mediated conversion of adenine nuc

102 t Group B Streptococcus expresses a specific ecto-5'-nucleotidase necessary for its pathogenicity and

103 ggest that specific NTPDases, in tandem with ecto-5'-nucleotidase, not only terminate P2 receptor act

104 Ecto-5'-nucleotidase (NT5E) catalyzes dephosphorylation

105 Prostatic acid phosphatase (PAP) and ecto-5'-nucleotidase (NT5E) hydrolyze extracellular AMP

106 Thereby, we demonstrate that ecto-5'-nucleotidase (NT5e) is specifically expressed in

107 CD73, an ecto-5'-nucleotidase (NT5E), serves as an immune checkpo

108 Ecto-5'-nucleotidase (NT5E, CD73) is a membrane-anchored

109 or (A(2B)R) after hydrolysis to adenosine by ecto-5'-nucleotidase (NT5E, CD73) or prostatic acid phos

110 fter obtaining IRB permission, expression of ecto-5'-nucleotidase (NT5E, CD73) was assessed in matche

111 uption was mediated by altered expression of ecto-5'-nucleotidase (Nt5e, gene encoding for CD73).

112 aste stimulation mainly by the action of the ecto-5'-nucleotidase, NT5E, and to a lesser extent, pros

113 tic triglyceride content, while mice lacking ecto-5'-nucleotidase or adenosine A1 or A2B receptors we

114 In this study, we show that CD73 (ecto-5'-nucleotidase) plays an important role in regulat

115 bs that target the cell-surface enzyme CD73 (ecto-5'-nucleotidase) reduce growth of primary tumors an

116 NAD+-dependent transcriptional repression of ecto-5'-nucleotidase, solute carrier family 12 member 8,

117 ificantly facilitated in the presence of the ecto-5'-nucleotidase substrate 5'-AMP.

118 CD73 is an ecto-5' nucleotidase that catalyzes the terminal phospho

119 bition by the upstream metabolite ADP of the ecto-5'-nucleotidase that converts AMP to adenosine intr

120 used mice that lack the CD73 gene (encoding ecto-5'-nucleotidase that converts AMP to adenosine) to

121 CD73, an ecto-5'-nucleotidase that converts AMP to adenosine, is

122 dicated that elevated expression of CD73, an ecto-5'-nucleotidase that generates adenosine, correlate

123 CD73 is a cell surface ecto-5'-nucleotidase that generates extracellular adenos